Current advances in cell therapeutics: a biomacromolecules application perspective

Adeyemi, Samson A.; Choonara, Yahya E.

doi:10.1080/17425247.2022.2064844

Cited by 8 publications

(7 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation therapy for OSCC involves ionizing or high-energy photons to kill cancer cells. Surgical procedures are followed if the tumor is local and early ( Gharat et al, 2016 ; Adeyemi and Choonara, 2022 ). The expression of EGFR and COX-2 is known to upregulate in oral cancer.…”

Section: Discussionmentioning

confidence: 99%

Cinnamomum zeylanicum Extract and its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects via Inhibition of Multiple Cellular Pathways

et al. 2022

View full text Add to dashboard Cite

Cinnamomum zeylanicum is a tropical plant with traditional medicinal significance that possesses antimicrobial, antifungal, anti-parasitic, and anti-tumor properties. Here, we have elucidated the anti-tumor effects of Cinnamomum zeylanicum extract (CZE) and its bioactive compound cinnamaldehyde (CIN) on oral cancer and elucidated underlying molecular mechanisms. Anti-tumor activities of CZE and CIN were demonstrated by various in vitro experiments on oral cancer cells (SCC-4, SCC-9, SCC-25). The cell proliferation, growth, cell cycle arrest, apoptosis, and autophagy were analyzed by MTT, clonogenic assay, propidium iodide, annexin-V-PI, DAPI, and acridine orange staining, respectively. The binding affinity of CIN towards dihydrofolate reductase and p38-MAP kinase alpha was analyzed by molecular docking. Western blot assay was performed to assess the alteration in the expression of various proteins. CZE and CIN treatment significantly inhibited the growth and proliferation of oral cancer cells in a dose-dependent manner. These treatments further induced apoptosis, cell cycle arrest, and autophagy. CZE and CIN inhibited the invasion and cytoplasmic translocation of NF-κB in these cell lines. CIN showed a high affinity to MAP kinase P38 alpha and dihydrofolate reductase with binding affinities of −6.8 and −5.9 kcal/mol, respectively. The cancer cells showed a decreased expression of various PI3k-AKT-mTOR pathways related to VEGF, COX-2, Bcl-2, NF-κB, and proteins post-treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Cinnamomum zeylanicum Extract and its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects via Inhibition of Multiple Cellular Pathways

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This issue is commonly overcome by cell encapsulation into polymeric materials which provides a means of implanting and maintaining the therapeutic cells at the desired location, while simultaneously ensuring the transport of nutrients into the implant and of therapeutic agents outside of it 7 . In addition, it allows for lower doses and potentially less side effects [8][9][10] . The idea was first successfully applied in preclinical studies with encapsulated pancreatic islet cells to control diabetes 11 .…”

Section: Introductionmentioning

confidence: 99%

“…Since then, research with encapsulated mammalian cells has been carried out in other fields, such as degenerative bone disease, hepatic disease, neurological disease, cancer 12,13 and urate homeostasis, to name a few 8,14,15 . Although the gap to regulatory approval of encapsulated cell therapy has not been closed yet 9,16 , several clinical trials are underway, for example with encapsulated genetically modified cells which release neurotrophic factors for neurodegenerative diseases 17,18 . Additionally, other application areas are opening up in encapsulated cell therapy, such as the use of encapsulated cells for ocular drug delivery 19 or encapsulation of stem cells for regenerative medicine [20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

“…Hydrogels typically used for cell encapsulation can be of biological or synthetic origin 8,10 . Among the former, the biomacromolecules of choice are usually polysaccharides, such as alginate, agarose and hyaluronic acid, and proteins, among which collagen stands out as the main component of the ECM, alongside others such as fibrin and elastin 9,16 . Synthetic polymers, on the other hand, have the advantage of easier processing and better mechanical stability 24 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Engineering a material-genetic interface as safety switch for embedded therapeutic cells

Jerez‐Longres

Gómez-Matos

Becker

et al. 2023

Preprint

View full text Add to dashboard Cite

Encapsulated cell-based therapies involve the use of genetically-modified cells embedded in a material in order to produce a therapeutic agent in a specific location in the patient's body. This approach has shown great potential in animal model systems for treating diseases such as type I diabetes or cancer, with selected approaches having been tested in clinical trials. Despite the promise shown by encapsulated cell therapy, though, there are safety concerns yet to be addressed, such as the escape of the engineered cells from the encapsulation material and the resulting production of therapeutic agents at uncontrolled sites of the body. For that reason, there is great interest in the implementation of safety switches that protect from those side effects. Here, we develop a material-genetic interface as safety switch for engineered mammalian cells embedded into hydrogels. Our switch allows the therapeutic cells to sense whether they are embedded in the hydrogel by means of a synthetic receptor and signaling cascade that link transgene expression to the presence of an intact embedding material. The system design is highly modular, allowing its flexible adaptation to other cell types and embedding materials. This autonomously acting switch constitutes an advantage over previously described safety switches, which rely on user-triggered signals to modulate activity or survival of the implanted cells. We envision that the concept developed here will advance the safety of cell therapies and facilitate their translation to clinical evaluation.

show abstract

“…Common biomacromolecular antitumor drugs include monoclonal antibodies, recombinant protein drugs and vaccines ( 5 ). These biomacromolecular drugs have some shortcomings in clinical use: i) Lack of selectivity for targeted lesion tissues in contrast to normal tissues, which may cause serious adverse reactions; ii) most drugs cannot enter cells to exert an antitumoral effect and iii) their mechanism of action on tissues, organs, cells and molecules within the body is frequently uncertain, therefore it is difficult to evaluate their efficacy ( 6 ). These factors lead to unsatisfactory clinical therapeutic effects of biomacromolecular drugs.…”

Section: Introductionmentioning

confidence: 99%

Metformin: A promising drug for human cancers (Review)

Huang

Zhao

et al. 2022

Oncol Lett

View full text Add to dashboard Cite

Small-molecule chemical drugs are of great significance for tumor-targeted and individualized therapies. However, the development of new small-molecule drugs, from basic experimental research and clinical trials to final application in clinical practice, is a long process that has a high cost. It takes at least 5 years for most drugs to be developed in the laboratory to prove their effectiveness and safety. Compared with the development of new drugs, repurposing traditional non-tumor drugs can be a shortcut. Metformin is a good model for a new use of an old drug. In recent years, the antitumor efficacy of metformin has attracted much attention. Epidemiological data and in vivo , and in vitro experiments have shown that metformin can reduce the incidence of cancer in patients with diabetes and has a strong antagonistic effect on metabolism-related tumors. Recent studies have shown that metformin can induce autophagy in esophageal cancer cells, mainly by inhibiting inflammatory signaling pathways. In recent years, studies have shown that the antitumor functions and mechanisms of metformin are multifaceted. The present study aims to review the application of metformin in tumor prevention and treatment.

show abstract

Current advances in cell therapeutics: a biomacromolecules application perspective

Cited by 8 publications

References 186 publications

Cinnamomum zeylanicum Extract and its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects via Inhibition of Multiple Cellular Pathways

Cinnamomum zeylanicum Extract and its Bioactive Component Cinnamaldehyde Show Anti-Tumor Effects via Inhibition of Multiple Cellular Pathways

Engineering a material-genetic interface as safety switch for embedded therapeutic cells

Metformin: A promising drug for human cancers (Review)

Contact Info

Product

Resources

About